Margaret Hamburg: The Public Health Commissioner
This article was originally published in RPM Report
An interview with newly confirmed FDA Commissioner Margaret Hamburg.
You may also be interested in...
Steven Grossman argues that the former commissioner possessed the credentials to be out front on the pricing issue, unlike other recent FDA commissioners and the current holder of the office.
FDA is beginning to solicit input from the medical community on review issues for a multi-ingredient cardiovascular product designed to control hypertension, platelet aggregation and cholesterol levels. The key issue is whether convenience and broad access make up for loss of individualized dosing. That is an important debate in the era of personalized medicine.
The tainted FDA review and approval of a small medical device-a meniscal repair scaffolding--may have some important implications for drug reviews in the future and the checks-and-balances structure of the agency.